Quantification of plasma β-catenin mRNA in colorectal cancer and adenoma patients
Quantification of plasma β-catenin mRNA in colorectal cancer and adenoma patients
复制标题
DOI：
10.1158/1078-0432.ccr-1168-3
复制
发表时间：
2004-03-01
影响因子：
11.5
通讯作者：
Lo, YMD
中科院分区：
文献类型：
--
作者：
Wong, SCC;Lo, SFE;Lo, YMD
目的：大肠癌是癌症死亡的重要原因。在此，我们将研究重点放在与结直肠癌发生有关的β-连环蛋白基因上，并使用定量逆转录酶-PCR检测结直肠癌和腺瘤患者血浆中是否可检测到β-连环蛋白mRNA。对58例结直肠癌患者、49例结直肠腺瘤患者、49例结直肠癌患者和49例结直肠癌患者的血浆β-连环蛋白mRNA进行了检测，和43名明显正常的受试者使用跨内含子引物和Taqman探针。研究了五个临床病理参数，并与血浆β-连环蛋白mRNA浓度相关。此外，还对19例结直肠癌术后患者的血浆β-catenin mRNA进行了检测，以进一步证明该检测的临床实用性。（范围：1480- 933，100）、1218（范围：541- 2，254）和291（范围：0- 1，366）拷贝/ml血浆。统计学分析表明，血浆β-catenin mRNA浓度与肿瘤分期相关，而与性别、年龄、淋巴结状态和分化程度无关。此外，血浆β-catenin mRNA浓度显着下降后，肿瘤切除16 19（84%）结直肠癌patients.Conclusions：我们得出结论，血浆β-catenin mRNA可能作为结直肠癌的标志物。
Purpose: Coloreetal cancer is an important cause of cancer deaths. Here, we focused our investigation on the beta-catenin gene which is implicated in colorectal carcinogenesis and tested whether beta-catenin mRNA is detectable in the plasma of colorectal carcinoma and adenoma patients using quantitative reverse transcriptase-PCR.Experimental Design: Plasma beta-catenin mRNA was measured from 58 colorectal carcinoma patients, 49 colorectal adenoma patients, and 43 apparently normal subjects using intron-spanning primers and Taqman probes. Five clinicopathological parameters were studied and correlated with plasma beta-catenin mRNA concentration. Additionally, 19 colorectal carcinoma patients after tumor removal were also recruited for plasma beta-catenin mRNA measurement to further demonstrate the clinical usefulness of this test.Results: beta-catenin mRNA was detected with median concentrations of 8737 (range: 1480-933,100), 1218 (range: 541-2,254) and 291 (range: 0-1,366) copies/ml plasma in colorectal carcinoma, colorectal adenoma, and apparently normal subjects, respectively. Statistical analysis demonstrated that plasma beta-catenin mRNA concentration was correlated to tumor stage but not sex, age, lymph node status, and degree in differentiation. Moreover, plasma beta-catenin mRNA concentration decreased significantly after tumor removal in 16 of 19 (84%) colorectal carcinoma patients.Conclusions: We conclude that plasma beta-catenin mRNA may potentially serve as a marker for colorectal cancer.